Kathiawad Today

Oncolytic Virus Cancer Therapy Pipeline Insight, 2022

 Breaking News
  • No posts were found

Oncolytic Virus Cancer Therapy Pipeline Insight, 2022

June 28
01:30 2022
Oncolytic Virus Cancer Therapy Pipeline Insight, 2022

DelveInsight’s Oncolytic Virus Cancer Therapy Pipeline Insight 2022 report provides comprehensive global coverage of available, marketed, and pipeline Oncolytic Virus Cancer Therapy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Oncolytic Virus Cancer Therapy pipeline domain.

 

Oncolytic Virus Cancer Therapy: An Overview

Oncolytic Virus Cancer Therapies are virus-based cancer therapies that infect and kill cancer cells, acting as in situ cancer vaccines by releasing tumor-specific antigens. Cancerous viruses like myxoma virus and reovirus have a natural preference for tumor cells while being nonpathogenic to healthy human cells. Other Oncolytic Viruses, such as adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), on the other hand, have been genetically altered to act as vectors to increase anti-tumor immune responses. Oncolytic viruses’ therapeutic efficiency is dependent on two major mechanisms of action: To begin, oncolytic viruses can limit tumor cell protein production and kill infected tumor cells by self-replication. Oncolytic viruses maintain self-replication after viral infection until the cell explodes; second, Oncolytic viruses can attract and activate tumor-infiltrating immune cells by releasing a significant number of tumor antigens and secreting cytokines. Oncolytic Virus Cancer Therapies can be utilized for both cancer diagnosis and cancer treatment. Many preclinical and clinical studies have been conducted to assess the anti-tumor efficacy of various Oncolytic Viruses as monotherapy and in combination therapy.

 

Download a sample copy of the market report @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Key highlights of the Oncolytic Virus Cancer Therapy Pipeline Report

  • DelveInsight’s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 70+ active players working to develop 100+ pipeline therapies for Oncolytic Viruses Cancer treatment.
  • In December 2021, Transgene announced that AstraZeneca had exercised its first license option for an Invir.IO™ oncolytic virus (OV) developed from their on-going OV collaboration. The exercise of this option for an OV, integrating an undisclosed transgene, resulted in Transgene receiving an $8 million payment from AstraZeneca.
  • In December 2021, Sorrento Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted clearance to proceed with a Phase 1b clinical trial using STI-1386, Seprehvec™, entitled “Dose Escalation Study of the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Patients with Relapsed or Refractory Solid Tumors.
  • In April 2022, OncoMyx Therapeutics announced the presentation of new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2022 (April 8-13). The data presented at AACR 2022 demonstrate that OncoMyx’s myxoma virus multi-armed with IL-12 and decorin infects and kills human multiple myeloma cells in vitro and demonstrates dose responsive efficacy after intravenous (IV) administration in a mouse model of multiple myeloma.

 

The Oncolytic Virus Cancer Therapy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Oncolytic Virus Cancer Therapy products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Oncolytic Virus Cancer Therapy pipeline landscape.

 

Oncolytic Virus Cancer Therapy Therapeutics Assessment

The Oncolytic Virus Cancer Therapy Pipeline report proffers an integral view of the Oncolytic Virus Cancer Therapy emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Oncolytic Virus Cancer Therapy Emerging Drugs

CG0070: CG Oncolgy

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.

ONCOS-102: Targovax

ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA. 

 

Oncolytic Viruses for Cancer Treatment

Besides several advantages of Oncolytic viruses as antitumor therapy, there are still many challenges which needs to be solved. Following are few hurdles that needs to be answered for translation of these therapies:

• Choosing Optimal Oncolytic virus Species

• Efficient Oncolytic virus Delivery (Local or Systemic)

• Enhancing Intra tumoral Oncolytic virus Infiltration and Diffusion

• Anti-Viral Immunity

• Immunosuppressive tumor microenvironment

 

Request a sample copy of the report @ Oncolytic Virus Cancer Therapy Pipeline Outlook

 

Oncolytic Virus Cancer Therapy Pipeline: Phases

DelveInsight’s report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Oncolytic Virus Cancer Therapy Pipeline Companies

• Affinia Therapeutics

• Lacerta Therapeutics

• Lokon Pharma AB

• Merck Sharp & Dohme Corp.

• Wuhan Binhui Biotechnology

• CG oncology

• BioVex Limited

• Oncolys BioPharma Inc.

• Replimmune

• Transgene

• Sorrento therapeutics

• ORCA therapeutics

• TILT Biotherapeutics

• Bioeclipse therapeutics

• Oncolys BioPharma

• Oncorus

• DNAtrix

• OncoMyx

• Vyriad

• VCN Biosciences

• Boehringer Ingelheim

• IconOVir

• Immugene

• AbbVie

• Turnstone Biologics, and several others

 

Explore more about the report- https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021

 

Table of Content

  • Introduction
  • Executive Summary
  • Oncolytic Virus Cancer Therapy: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Oncolytic Virus Cancer Therapy Collaboration Deals
  • Late Stage Products (Phase III) 
  • CG0070: CG Oncolgy
  • Mid Stage Products (Phase II)
  • ONCOS-102: Targovax
  • Early Stage Products (Phase I/II) 
  • Drug Name: Company Name
  • Inactive Products
  • Oncolytic Virus Cancer Therapy Key Companies
  • Oncolytic Virus Cancer Therapy Key Products
  • Oncolytic Virus Cancer Therapy- Unmet Needs
  • Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
  • Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
  • Oncolytic Virus Cancer Therapy Analyst Views
  • Oncolytic Virus Cancer Therapy Key Companies
  • Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/